
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Chicago - The dermatological ecology of South Africa, a context considerably different from its North American counterpart, was discussed at this year's L'Oreal Ethnic Skin and Hair Conference here from Sept. 19 to 21, 2003.